Navigation Links
Regenicin CEO to Participate in Live Webcast at OneMedForum Business Development and Finance Conference, January 11th at 4:00 PM PST
Date:1/11/2011

LITTLE FALLS, N.J., Jan. 11, 2011 /PRNewswire/ -- Regenicin, Inc. (OTC Bulletin Board: RGIN) a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs, will present at the 4th annual OneMedForum at the Sir Francis Drake Hotel in San Francisco today, Tuesday, January 11th.  Regenicin's CEO, Randall McCoy, will present Regenicin's core business model and strategic approach for bringing new regenerative medicine products to market. The presentation will take place at 4:00 PM PST in the hotel's Renaissance Room and can also be viewed through a live webcast at the following link http://www.ustream.tv/channel/onemedforum.

The 4th Annual OneMedForum

OneMedForum San Francisco 2011, runs concurrently with the J.P. Morgan conference that provides efficient access to the companies that shape the future of the rapidly changing healthcare landscape. The conference's mission is to bring together investors, business development executives, and the brightest new ideas and emerging healthcare and life science companies. Panel sessions will provide Insights for investors to better understand and identify prospective investment opportunities among the 100+ emerging public and private companies that will present over the two and a half days.

About Regenicin

Regenicin, Inc., (OTC Bulletin Board: RGIN) is a biotechnology company specializing in the development of and commercialization of regenerative cell therapies to restore the health of damaged tissues and organs. Regenicin, which was founded in 2010, has assembled a world class team with a proven track record for developing and bringing innovative medical devices and biotechnology products to market. Regenicin is playing a critical role in the development of the therapeutic candidate, PermaDerm™, an exciting breakthrough technology that uses the patient's own skin cells to generate living, tissue-engineered skin for the treatment of chronic burns. The company is publicly traded with headquarters in New Jersey. Additional information can be found in the company's filings with the Securities and Exchange Commission located at www.sec.gov.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Regenicin, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Regenicin COO Receives Citizenship Award from VFW Post 1 in Colorado
2. Regenicin Announces Closing of Private Placement Transaction
3. Regenicin Changes Its Ticker Symbol to RGIN.OB
4. Regenicin Presentation Now Available Online at RetailInvestorConferences.com
5. Regenicin to Present at Event Celebrating Advancements in Regenerative Medicine
6. Regenicin to Present Live at RetailInvestorConferences.com on November 4th
7. Regenicin Appoints Renowned New York Dermatologist, Dr. Gervaise Gerstner to Scientific Advisory Board
8. Regenicin to Form Scientific Advisory Board
9. Regenicin Names Former U.S. Marine Corp Operations Officer, Christopher Hadsall, Chief Operating Officer
10. Former Fujifilm Medical Systems USA Executive John J. Weber Agrees to Join Regenicin™ as a Member of Its Board of Directors and Interim CFO
11. Regenicin Completes Acquisition of Worldwide Exclusive Know-How Technology License from Lonza Walkersville
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
(Date:10/10/2017)... PA (PRWEB) , ... October 10, 2017 , ... ... year’s recipients of 13 prestigious awards honoring scientists who have ... presented in a scheduled symposium during Pittcon 2018, the world’s leading conference and ...
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer ... first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , With ... with the challenge of how to continue to feed a growing nation. At the ...
(Date:10/9/2017)... Arizona (PRWEB) , ... October 09, 2017 , ... ... Kindred, a four-tiered line of medical marijuana products targeting the needs of consumers ... and packaging of Kindred takes place in Phoenix, Arizona. , As operators of ...
Breaking Biology Technology:
(Date:5/16/2017)...  Veratad Technologies, LLC ( www.veratad.com ), an innovative ... verification solutions, announced today they will participate as a ... thru May 17, 2017, in Washington D.C.,s ... Identity impacts the lives of billions ... evolving digital world, defining identity is critical to nearly ...
(Date:4/18/2017)... SUNNYVALE, Calif. , April 18, 2017  Socionext Inc., a ... prototype of a media edge server, the M820, which features the ... face recognition software provided by Tera Probe, Inc., will be showcased ... and at the NAB show at the Las Vegas ... ...
(Date:4/11/2017)... Research and Markets has announced the addition of the "Global ... ... at a CAGR of 30.37% during the period 2017-2021. ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
Breaking Biology News(10 mins):